News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Jonathan Cohen discusses hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society
Photo from Jonathan Cohen/LinkedIn
Apr 13, 2024, 14:18

Jonathan Cohen discusses hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society

Jonathan Cohen, Director of Clinical Research at Sharett Institute of Oncology of Hadassah Medical Center, shared on LinkedIn:

“I had the opportunity to discuss various topics in hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society (ISCORT).

Some points of discussion:

  • Should all HCC patients undergo biopsies?
    – This will probably become SOC soon with ADC’s and other biomarker-driven therapies; but not yet.
  • When should systemic therapies be introduced?
    – Adjuvant data is not ripe, but I would strongly consider when loco-regional disease recurs. Survival data will be crucial.
    – Neoadjuvant treatment makes sense. Awaiting data.
    – Downstaging with ICI before liver transplant – some ongoing single institution studies. Risk of rejection? Loss of systemic protection due to immune-suppression? vs. potential for cure?
  • How should increased LFT’s be handled in HCC patients receiving ICI?
    – Don’t rush to label as irAE.
  • What’s going on in the clinical research arena for HCC?
    – ADC’s
    – Immune-cell engagers
    – Novel combinations
    – Personalized neoantigen vaccine.”

No alt text provided for this image

View additional information.
Source: Jonathan Cohen/LinkedIn

ADCs Antibody drug conjugates cancer clinical research Hadassah Medical Center HCC hepatocellular carcinoma immune checkpoint inhibition immune related adverse events irAE ISCORT Jonathan Cohen LFTs liver function tests neoadjuvant treatment OncoDaily Oncology Sharett Institute of Oncology sraeli oncology society
Special Coverage
Insight
Dec 19, 2024, 08:27
What role does mentorship play in building resilience? - ESMO
Blog
Dec 19, 2024, 08:16
The U.S. House of Representatives released text of the FY25 Continuing Resolution - ACS CAN
Insight
Dec 19, 2024, 08:12
Talha Badar: ASH24 abstract in acute leukemia and MDS
Blog
Dec 19, 2024, 08:08
T790M resistance mutations in EGFR+ lung cancer - EGFR Positive Lung Cancer UK
Positive
Dec 19, 2024, 08:03
Eric K. Singhi: Honored to be recognized as this year’s Emerging Leader by MUSC Alamni
Blog
Dec 19, 2024, 07:57
Marilyn Bui: Moffitt Cancer Center achieved the highest patient satisfaction score this year
Blog
Dec 19, 2024, 07:51
Laura Bukavina: The use of TMT for localized bladder cancer in octogenarians
Opinion
Dec 19, 2024, 07:45
Gustavo Viani: Stereotactic Body Radiation Therapy - Does scheduling matter?
Blog
Dec 19, 2024, 07:41
IMPACT Malignant Hematology Webinar on the evolving treatment landscape of lower-risk MDS - Vanderbilt-Ingram Cancer Center
Societies
Dec 19, 2024, 07:38
ASCOGI25 abstract titles are now available
Insight
Dec 19, 2024, 07:27
Geoffrey Shapiro Honored with MSCO Distinguished Researcher Award
Drugs
Dec 19, 2024, 07:24
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy®